Navigation Links
InVitria Reveals Technology to Optimize Hybridoma Production Performance
Date:4/22/2009

Article in Spring edition of Bioprocessing Journal reports InVitria's recombinant human serum albumin (Cellastim) and recombinant lactoferrin (Lacromin) cell culture supplements optimize cell growth and productivity in hybridoma cells.

Fort Collins, CO (PRWEB) April 22, 2009-- Recent studies using both classical media and the leading commercial serum-free hybridoma media formulations proved that InVitria's cell culture supplements optimized cell growth and productivity of hybridoma cells.1 Further, the studies revealed that Cellastim supports cell adaptation and survival in chemically-defined media.

Additional findings from the study showed that Cellastim improved the cell growth and productivity in long-term culture. In a 25-day period, cell doublings in Cellastim-supplemented media were twice that of media without Cellastim. Also, antibody production was 65% higher in the commercial media with Cellastim while cells supplemented with Cellastim grew to higher density than those in unsupplemented media.

"This research incorporated classical media as well as several leading commercial media available on the market," said Dr. Steve Pettit, the project's lead researcher. "We achieved optimal cell density and quicker doubling times as well as better cell productivity when Cellastim was added to these media. We also reported that Lacromin improves hybridoma cell culture performance."

Lacromin increased cell density in supplemented media nearly double compared to that of media without Lacromin supplementation. A significant increase in antibody production was recognized in all Lacromin-treated media, exceeding the level achieved with 5% fetal bovine serum (FBS).

"This research supports what customers have been reporting from their use of Cellastim and Lacromin for hybridoma cell culture," said InVitria President and CEO Scott Deeter. "Cellastim has been shown to not only optimize hybridoma performance, but also outperform other sources of native and recombinant albumin."

To obtain a copy of the above-mentioned article entitled, "Enhanced Growth and Productivity of a Hybridoma with Recombinant Human Albumin and Lactoferrin," please contact InVitria at info(at)InVitria(dot)com or 1-800-916-8311.

About InVitria
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research and diagnostics.

1Pettit S, Santos M, Tanner T, Huang N. Enhanced Growth and Productivity of a Hybridoma with Recombinant Human Albumin and Lactoferrin. BioProcessing Journal 2009; 8(1): 50-55.

###

Read the full story at http://www.prweb.com/releases/hybridomacells/hybridomaproduction/prweb2350604.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. InVitria Headlines Sponsorship of WilBio's Waterside Conference
2. InVitria Announces Launch of Recombinant Albumin for Diagnostics
3. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
4. InVitria's Cellastim Delivers Superior Results in CHO Cell Culture
5. InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego
6. InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting
7. InVitria to Present at WilBio's International Cell Engineering Meeting
8. Retirement Living TV Reveals: Sex Is The Real Fountain of Youth
9. New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies
10. New Research Reveals Need for Doctors to Know About Medical Tattoos
11. Study Reveals How Salmonella Hijacks Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... this summer’s edition of “Vision & Hearing,” advocating for active, healthy lifestyles and ... on resources available for individuals with hearing impairments and shares the latest innovations ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, a northern ... the greater DC region, is inaugurating a “New Leash On Life” charity initiative ... training them to be companions for veterans in need. , The Semper K9 ...
(Date:8/18/2017)... ... 18, 2017 , ... Moore Insurance, a Houston area agency ... is launching a regional charity effort to provide publicity assistance and generate donations ... Tumor Foundation (PBTF) has raised nearly $30 million in donations that has been ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: